A successful desensitization in an adult patient with ARA-C infusion reaction

Introduction Cytarabine (ARA-C) is an antimetabolite agent used especially in the treatment of hematologic malignancies. Infusion reactions have an important place among the side effects that may occur due to treatment. Clinical findings of infusion reactions resemble allergic reactions. Case Report...

Full description

Saved in:
Bibliographic Details
Published in:Journal of oncology pharmacy practice 2024-06, Vol.30 (4), p.780-782
Main Authors: Akgul Balaban, Yasemin, Inan, Mustafa Ilker, Selcuk, Ali, Kartal, Ozgur, Zengin, Haydar, Bulduk, Tuba
Format: Article
Language:English
Subjects:
Acute lymphoblastic leukemia
Allergies
Antimetabolites, Antineoplastic - administration & dosage
Antimetabolites, Antineoplastic - adverse effects
Cytarabine
Cytarabine - administration & dosage
Cytarabine - adverse effects
Desensitization, Immunologic - methods
Drug Hypersensitivity - etiology
Drug Hypersensitivity - therapy
Humans
Infusions, Intravenous
Lymphocytes B
Male
Malignancy
Middle Aged
Patients
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - immunology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Cytarabine (ARA-C) is an antimetabolite agent used especially in the treatment of hematologic malignancies. Infusion reactions have an important place among the side effects that may occur due to treatment. Clinical findings of infusion reactions resemble allergic reactions. Case Report 47-year-old male patient with a diagnosis of B-cell Acute Lymphoblastic Leukaemia developed infusion reaction during ARA-C treatment. Management & Outcome There was no alternative treatment option for his existing malignant disease, we decided ARA-C desensitization. Discussion We would like to describe a successful desensitization protocol in an adult patient who experienced a reaction during ARA-C infusion.
ISSN:1078-1552
1477-092X
1477-092X
DOI:10.1177/10781552241242691